Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLAGE: First-line Therapy in Elderly mCRC
NCT03828227Phase 3Active, not recruiting
- Sponsor
- GERCOR
- Start
- Jun 2019
- Primary completion
- Nov 2023
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin and capecitabine in metastatic colorectal cancer (mCRC) (3 arms), sponsored by GERCOR. Primary endpoint: Health-related quality of life at 6 months. Started Jun 2019; status: active, not recruiting.
02
Drugs
oxaliplatincapecitabine
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03828227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03828227.